✦ LIBER ✦

Factors influencing response to second-line treatment with teniposide (VM26) in patients with progressive small cell lung cancer (SCLC)

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

216 Second-line treatment regimen in pat

✍ Orel, N.F.; Gorbunova, V.A.; Bychkov, M.B.; Smirnova, N.B. 📂 Article 📅 1997 🏛 Elsevier Science 🌐 English ⚖ 149 KB

Unexpected high toxicity in a phase II s

📂 Article 📅 1989 🏛 Elsevier Science 🌐 English ⚖ 184 KB

Unexpected high toxicity in a phase II s

📂 Article 📅 1989 🏛 Elsevier Science 🌐 English ⚖ 153 KB

Unexpected high toxicity in a phase II s

✍ Cerny, T.; Pedrazzini, A.; Joss, R.A.; Brunner, K.W. 📂 Article 📅 1988 🏛 Elsevier Science ⚖ 390 KB

Pooled analysis of topotecan (T) in the

✍ Eckardt, J.; Depierre, A.; Ardizzoni, A.; Von Pawel, J.; Fields, S. 📂 Article 📅 1997 🏛 Elsevier Science 🌐 English ⚖ 212 KB

P-565 Phase II study of Fenretinide in p

✍ Schneider, Bryan; Worden, Francis P.; Gadgeel, Shirish M.; Hodges, Collette M.; 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 178 KB